We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Singulex Advances Conversation on Personalized Medicine
News

Singulex Advances Conversation on Personalized Medicine

Singulex Advances Conversation on Personalized Medicine
News

Singulex Advances Conversation on Personalized Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Singulex Advances Conversation on Personalized Medicine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Singulex Inc., a company focused on advancing technologies for early disease detection, has announced that its CEO, Philippe Goix, Ph.D., is chairing a panel on personalized medicine at the Think Tomorrow Today Summit, sponsored by ThinkPanmure.

Participants on the panel, entitled "Just for Me: Personalized Medicine," include Michael McKenna, Ph.D., CSO of Tethys Biosciences and Kathryn Phillips, Ph.D., professor of health economics & health services research at UCSF.

"While pharmacogenomics represent much of the current activity in personalized medicine, they are only the tip of the iceberg," said Philippe Goix, CEO of Singulex.

"The utility of protein biomarkers could soon eclipse that of pharmacogenomics, allowing much earlier disease detection and also enabling pharmaceutical companies to identify what patient populations will respond to their drug and then to monitor those patients to measure disease regression," Goix said.

Singulex has technology that increases the clinical utility of biomarkers using immunoassay technologies. Through collaborations with pharmaceutical and biotechnology companies and academic researchers, the company has shown specifically that the biomarker c Troponin I (cTnI), a validated biomarker for cardiac necrosis, can be detected in healthy people.

Singulex can also measure small changes in cTnI levels that indicate stress to the heart, such as during treadmill stress tests, which other technologies cannot do.

Advertisement